RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer

2011 ◽  
Vol 105 (4) ◽  
pp. 425-430 ◽  
Author(s):  
Chunri Yan ◽  
Young-Won Kim ◽  
Yun-Sok Ha ◽  
Isaac Yi Kim ◽  
Yong-June Kim ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Disease Progression ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

scholarly journals Three-gene signature predicts disease progression of non-muscle invasive bladder cancer

2011 ◽  
Vol 2 (4) ◽  
pp. 679-684 ◽  
Author(s):  
PILDU JEONG ◽  
YUN-SOK HA ◽  
IN-CHANG CHO ◽  
SEOK-JOONG YUN ◽  
EUN SANG YOO ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Disease Progression ◽  
Gene Signature ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

scholarly journals A Four-Gene Signature Predicts Disease Progression in Muscle Invasive Bladder Cancer

2011 ◽  
Vol 17 (5-6) ◽  
pp. 478-485 ◽  
Author(s):  
Wun-Jae Kim ◽  
Seon-Kyu Kim ◽  
Pildu Jeong ◽  
Seok-Joong Yun ◽  
In-Chang Cho ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Disease Progression ◽  
Gene Signature ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

scholarly journals Mitofusin-2 Down-Regulation Predicts Progression of Non-Muscle Invasive Bladder Cancer

Diagnostics ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. 1500
Author(s):  
Antonella Cormio ◽  
Gian Maria Busetto ◽  
Clara Musicco ◽  
Francesca Sanguedolce ◽  
Beppe Calò ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Disease Progression ◽  
Bladder Tumor ◽  
Bladder Wall ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Mitofusin 2 ◽  
Clinical Issue ◽  
Expression Levels ◽  
Muscle Invasive

Identification of markers predicting disease outcome is a major clinical issue for non-muscle invasive bladder cancer (NMIBC). The present study aimed to determine the role of the mitochondrial proteins Mitofusin-2 (Mfn2) and caseinolytic protease P (ClpP) in predicting the outcome of NMIBC. The study population consisted of patients scheduled for transurethral resection of bladder tumor upon the clinical diagnosis of bladder cancer (BC). Samples of the main bladder tumor and healthy-looking bladder wall from patients classified as NMIBC were tested for Mfn2 and ClpP. The expression levels of these proteins were correlated to disease recurrence, progression. Mfn2 and ClpP expression levels were significantly higher in lesional than in non-lesional tissue. Low-risk NMIBC had significantly higher Mfn2 expression levels and significantly lower ClpP expression levels than high-risk NMIBC; there were no differences in non-lesional levels of the two proteins. Lesional Mfn2 expression levels were significantly lower in patients who progressed whereas ClpP levels had no impact on any survival outcome. Multivariable analysis adjusting for the EORTC scores showed that Mfn2 downregulation was significantly associated with disease progression. In conclusion, Mfn2 and ClpP proteins were found to be overexpressed in BC as compared to non-lesional bladder tissue and Mfn2 expression predicted disease progression.

Primary High-Grade Non-Muscle-Invasive Bladder Cancer: High NFκB Expression in Tumor Specimens Distinguishes Patients Who are at Risk for Disease Progression

2017 ◽  
Vol 25 (1) ◽  
pp. 225-231 ◽  
Author(s):  
Lampros Mitrakas ◽  
Stavros Gravas ◽  
Christos Papandreou ◽  
Georgios Koukoulis ◽  
Foteini Karasavvidou ◽  
...  
Keyword(s):  
At Risk ◽  
Bladder Cancer ◽  
Disease Progression ◽  
Invasive Bladder Cancer ◽  
High Grade ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

Disease progression among patients who receive available bladder preservation therapies after failure of BCG therapy in the SEER-Medicare data.

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 453-453
Author(s):  
Ashish M. Kamat ◽  
Mihaela V. Georgieva ◽  
Jinlin Song ◽  
Iryna Bocharova ◽  
Kun Qian ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Disease Progression ◽  
Mitomycin C ◽  
Radical Cystectomy ◽  
Interferon Alpha ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Bladder Preservation ◽  
Bcg Therapy ◽  
Muscle Invasive

453 Background: For patients with high-grade (HG) non-muscle invasive bladder cancer (NMIBC) who recur after Bacillus Calmette-Guérin (BCG) therapy, treatment options other than radical cystectomy have been limited. This study examined real-world utilization and outcomes of current bladder preservation therapies (BPT) after BCG treatment. Methods: We analyzed the SEER-Medicare database and identified patients diagnosed with HG NMIBC between 2008 and 2015 who received at least one BCG induction course (defined as ≥5 weekly instillations). Use of BPT within six months of the last consecutive BCG instillation was identified and included BCG + interferon alpha, docetaxel, doxorubicin, epirubicin, gemcitabine, mitomycin C, nab-paclitaxel, thiotepa, valrubicin, or their combinations. Progression was identified as initiation of treatment for muscle-invasive bladder cancer, radical cystectomy, or presence of metastases. Time to progression (TTP) was defined as time from BPT initiation to progression event. Progression-free survival (PFS) was assessed from BPT initiation and defined as the absence of progression or death due to bladder cancer. TTP and PFS were assessed using Kaplan-Meier analysis. Results: A total of 7,074 patients were diagnosed with HG NMIBC and received ≥ 5 BCG weekly induction instillations. Of these, 8.8% (620 patients) initiated BPT. The most commonly used agents were mitomycin C (66.0%), followed by BCG + interferon alpha (22.9%), valrubicin (4.0%), doxorubicin (2.9%), and gemcitabine (2.1%). Disease progression occurred in 18.7% of patients within 1 year of treatment initiation (40.5% due to metastases), 36.4% within 3 years (50.0% due to metastases), and 45.4% within 5 years (50.2% due to metastases). The rate of PFS was 80.9%, 61.8%, and 52.3% at 1, 3, and 5 years, respectively. Conclusions: High rates of metastatic disease are noted in HG NMIBC following available BPT treatments after failure of BCG therapy. A high unmet need remains for novel bladder-sparing therapies to improve outcomes in this difficult-to-treat population.

Sign in / Sign up

Export Citation Format

Share Document